[1] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression. Lancet 2020;395:1033-4.

[2] Matthay MA, Aldrich JM, Gotts JE. Treatment for Severe Acute Respiratory Distress Syndrome from COVID-19. Lancet Respir Med 2020;8:433-4.

[3] Yang X, Yu Y, Xu J, Shu PH, Xia J, Liu PH, et al. Clinical Course and Outcomes of Critically ill Patients with SARS-CoV-2 pneumonia in Wuhan, China: A Single-centered, Retrospective, Observational Study. Lancet Respir Med 2020;8:475-81.

[4] Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical Characteristics of 113 Deceased Patients with Coronavirus Disease 2019: Retrospective Study. BMJ 2020;368:m1295.

[5] Giani M, Seminati D, Lucchini A, Foti G, Pagni F. Exuberant Plasmocytosis in Bronchoalveolar Lavage Specimen of the First Patient Requiring Extracorporeal Membrane Oxygenation for SARS-CoV-2 in Europe. J Thorac Oncol 2020;15:e65-6.

[6] McVey M, Tabuchi A, Kuebler WM. Microparticles and Acute Lung Injury. Am J Physiol Lung Cell Mol Physiol 2012;303:L364-81.

[7] Takei Y, Yamada M, Saito K, Kameyama Y, Sugiura H, Makiguchi T, et al. Increase in Circulating ACE-Positive Endothelial Microparticles during Acute Lung Injury. Eur Respir J 2019;54:1801188.

[8] Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural Basis for the Recognition of SARS-CoV-2 by full-Length Human ACE2. Science 2020;367:1444-8.

[9] Ajamieh H, Farrell GC, McCuskey RS, Yu J, Chu E, Wong HJ, et al. Acute Atorvastatin is Hepatoprotective against Ischaemia-reperfusion Injury in Mice by Modulating eNOS and Microparticle Formation. Liver Int 2015;35:2174-86.

[10] Ajamieh H, Farrell G, Wong HJ, Yu J, Chu E, Chen J, et al. Atorvastatin Protects Obese Mice Against Hepatic Ischemia-reperfusion Injury by Toll-like receptor-4 Suppression and Endothelial Nitric Oxide Synthase Activation. J Gastroenterol Hepatol 2012;27:1353-61.

[11] McAuley DF, Laffey JG, O’Kane CM, Perkins GD, Mullan B, Trinder TJ, et al. Simvastatin in the Acute Respiratory Distress Syndrome. N Engl J Med 2014;371:1695-703.

[12] Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, et al. Acute respiratory Distress Syndrome Subphenotypes and Differential Response to Simvastatin: Secondary Analysis of a Randomised Controlled Trial. Lancet Respir Med 2018;6:691-8.

[13] Calfee CS, Sinha P. Phenotypes in acute respiratory distress syndrome: Moving towards precision medicine. Curr Opin Crit Care 2019;25:12-20.

[14] Mendieta G, Ben-Aicha S, Gutierrez M, Casani L, Aržanauskaitė M, Carreras F, et al. Intravenous Statin Administration during Myocardial Infarction Compared with Oral Post-infarct Administration. J Am Coll Cardiol 2020;75:1386-402.

[15] Gavazzoni M, Gorga E, Derosa G, Maffioli P, Metra M, Raddino R, et al. High-dose Atorvastatin Versus Moderate dose on Early Vascular Protection after STElevation Myocardial Infarction. Drug Des Devel Ther 2017;11:3425-34.

[16] Mohammadkhani N, Gharbi S, Rajanj HF, Farzaneh A, Mahjoob G, Hoseinsalari A, et al. Statins: Complex Outcomes but Increasingly Helpful Treatment Options for Patients. Eur J Pharmacol 2019;863:172704.